Hongyong Cao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7750120/publications.pdf

Version: 2024-02-01

26 papers	1,406 citations	686830 13 h-index	525886 27 g-index
29 all docs	29 docs citations	29 times ranked	1637 citing authors

#	Article	IF	Citations
1	An emerging function of circRNA-miRNAs-mRNA axis in human diseases. Oncotarget, 2017, 8, 73271-73281.	0.8	429
2	CircRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer. Molecular Cancer, 2018, 17, 137.	7.9	213
3	Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma. Cancer Biomarkers, 2018, 21, 299-306.	0.8	122
4	Circ-SFMBT2 promotes the proliferation of gastric cancer cells through sponging miR-182-5p to enhance CREB1 expression. Cancer Management and Research, 2018, Volume 10, 5725-5734.	0.9	85
5	Novel insights into circular RNAs in clinical application of carcinomas. OncoTargets and Therapy, 2017, Volume 10, 2183-2188.	1.0	57
6	Single-cell RNA sequencing in cancer: Applications, advances, and emerging challenges. Molecular Therapy - Oncolytics, 2021, 21, 183-206.	2.0	44
7	Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. Frontiers in Cell and Developmental Biology, 2021, 9, 694363.	1.8	42
8	The circ_0021977/miRâ€10bâ€5p/P21 and P53 regulatory axis suppresses proliferation, migration, and invasion in colorectal cancer. Journal of Cellular Physiology, 2020, 235, 2273-2285.	2.0	38
9	Single-cell RNA sequencing of immune cells in gastric cancer patients. Aging, 2020, 12, 2747-2763.	1.4	36
10	Upregulation of circ_0066444 promotes the proliferation, invasion, and migration of gastric cancer cells. OncoTargets and Therapy, 2018, Volume 11, 2753-2761.	1.0	29
11	The emerging landscape of circular RNAs in immunity: breakthroughs and challenges. Biomarker Research, 2020, 8, 25.	2.8	24
12	CircETFA upregulates CCL5 by sponging miR-612 and recruiting EIF4A3 to promote hepatocellular carcinoma. Cell Death Discovery, 2021, 7, 321.	2.0	17
13	Circ-EIF4G3 promotes the development of gastric cancer by sponging miR-335. Pathology Research and Practice, 2019, 215, 152507.	1.0	15
14	circCORO1C promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing the expression of PDâ€L1 through NFâ€ºB pathway. Journal of Clinical Laboratory Analysis, 2021, 35, e24003.	0.9	14
15	MFAP2 Promotes the Proliferation of Cancer Cells and Is Associated With a Poor Prognosis in Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2020, 19, 153303382097752.	0.8	13
16	Overexpression of lncRNA AFAP1â€‘AS1 promotes cell proliferation and invasion in gastric cancer. Oncology Letters, 2019, 18, 3211-3217.	0.8	10
17	Emerging Mechanisms and Treatment Progress on Liver Metastasis of Colorectal Cancer. OncoTargets and Therapy, 2021, Volume 14, 3013-3036.	1.0	10
18	Treatment of patients with cancer using PDâ€1/PDâ€L1 antibodies: Adverse effects and management strategies (Review). International Journal of Oncology, 2022, 60, .	1.4	9

#	Article	IF	Citations
19	Circular RNAs as novel rising stars with huge potentials in development and disease. Cancer Biomarkers, 2018, 22, 597-610.	0.8	8
20	Emerging Landscapes of Tumor Immunity and Metabolism. Frontiers in Oncology, 2020, 10, 575037.	1.3	8
21	WNT5a in Colorectal Cancer: Research Progress and Challenges. Cancer Management and Research, 2021, Volume 13, 2483-2498.	0.9	6
22	Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma. Journal of Oncology, 2022, 2022, 1-16.	0.6	6
23	Hsa_circ_0000081 promotes the function of gastric cancer through sponging hsa-miR-423-5p to influence 3-phosphoinositide-dependent kinase 1 expression. Bioengineered, 2022, 13, 8277-8290.	1.4	4
24	Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway. Journal of Oncology, 2022, 2022, 1-12.	0.6	2
25	Multiple roles of THY1 in gastric cancer based on data mining. Translational Cancer Research, 2020, 9, 2748-2757.	0.4	1
26	The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer. Frontiers in Surgery, 2022, 9, 895982.	0.6	1